Department of Cardiology, Second Affiliated Hospital of Xi'an Jiaotong University, Shaanxi Province, China.
Department of Radiology, Shaanxi Mineral Hospital, Shaanxi Province, China.
Nutrition. 2021 Nov-Dec;91-92:111405. doi: 10.1016/j.nut.2021.111405. Epub 2021 Jun 26.
High-dose intravenous vitamin C (HIVC) is a major concern when treating patients with coronavirus disease 2019 (COVID-19). The aim of this study was to assess the clinical efficacy of HIVC on hyperinflammation in patients with severe COVID-19.
This retrospective cohort study included hospitalized patients with severe COVID-19, a subset of whom was treated with HIVC. The medical records were screened for demographic data, laboratory findings, and medications, as well as initial and repeated values of multiple inflammatory markers for analysis.
A high percentage of patients presented with hyperinflammation based on inflammatory marker levels above the upper limit of normal (high-sensitivity C-reactive protein, 80.1%; interleukin-6, 91.5%; and tumor necrosis factor-α, 67.4%). Eighty-five (36%) patients received HIVC therapy. After treatment with HIVC, the levels of inflammatory markers displayed a significant decrease compared with those of patients without HIVC. Furthermore, the percentages of reduction in inflammatory marker levels were higher in patients receiving HIVC compared with those in patients treated without HIVC. Stepwise multiple linear regression analysis revealed that HIVC was independently associated with percentages of reduction in levels of inflammatory markers.
HIVC has the potential benefit of attenuating hyperinflammation by reducing inflammatory marker levels in patients with severe COVID-19.
在治疗 2019 冠状病毒病（COVID-19）患者时，大剂量静脉注射维生素 C（HIVC）是一个主要关注点。本研究旨在评估 HIVC 对重症 COVID-19 患者过度炎症的临床疗效。
这是一项回顾性队列研究，纳入了住院的重症 COVID-19 患者，其中一部分接受了 HIVC 治疗。对病历进行了筛选，以获取人口统计学数据、实验室结果和药物治疗情况，以及多个炎症标志物的初始和重复值以进行分析。
根据炎症标志物水平高于正常值上限（高敏 C 反应蛋白 80.1%、白细胞介素 6 91.5%和肿瘤坏死因子-α 67.4%），很大一部分患者表现出过度炎症。85 名（36%）患者接受了 HIVC 治疗。与未接受 HIVC 治疗的患者相比，接受 HIVC 治疗后，炎症标志物水平显著下降。此外，接受 HIVC 治疗的患者炎症标志物水平降低的百分比高于未接受 HIVC 治疗的患者。逐步多元线性回归分析表明，HIVC 与炎症标志物水平降低的百分比独立相关。
HIVC 通过降低重症 COVID-19 患者的炎症标志物水平，具有减轻过度炎症的潜在益处。
